|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500103956 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-09 15:09:11 |
|
注册时间: Date of Registration: |
2025-06-09 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
心脏瓣膜置换术患者术前衰弱管理方案的构建及实证研究 |
|
Public title: |
Construction and demonstration study of preoperative frailty management plan for patients undergoing cardiac valve replacement |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
心脏瓣膜置换术病人术前衰弱管理方案的构建及实证研究 |
|
Scientific title: |
Construction and demonstration study of preoperative frailty management plan for patients undergoing cardiac valve replacement |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李珊 |
研究负责人: |
周家梅 |
|
Applicant: |
Shan Li |
Study leader: |
Jiamei Zhou |
|
申请注册联系人电话: Applicant telephone: |
+86 188 8614 0047 |
研究负责人电话:
Study leader's |
+86 139 8499 9285 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
2742157958@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
2742157958@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
贵州省遵义市遵义医科大学大连路校区荟萃公寓 |
研究负责人通讯地址: |
贵州省遵义市汇川区大连路149号 |
|
Applicant address: |
Zunyi Medical University, Dalian Road Campus, Zunyi City, Guizhou Province |
Study leader's address: |
No. 149, Dalian Road, Huichuan District, Zunyi City, Guizhou Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
遵义医科大学护理学院 |
||
|
Applicant's institution: |
Zunyi Medical University School of Nursing |
||
|
研究负责人所在单位: |
遵义医科大学附属医院 |
||
|
Affiliation of the Leader: |
Affiliated Hospital of Zunyi Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KLLY-2024-233 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
遵义医科大学附属医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Affiliated Hospital of Zunyi Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-12-15 00:00:00 | ||
|
伦理委员会联系人: |
李树飞 |
||
|
Contact Name of the ethic committee: |
Li Shufei |
||
|
伦理委员会联系地址: |
贵州省遵义市汇川区大连路149号 |
||
|
Contact Address of the ethic committee: |
No. 149, Dalian Road, Huichuan District, Zunyi City, Guizhou Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 851 2860 8776 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
34621892@qq.com |
|
研究实施负责(组长)单位: |
遵义医科大学附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Affiliated Hospital of Zunyi Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
贵州省遵义市汇川区大连路149号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 149, Dalian Road, Huichuan District, Zunyi City, Guizhou Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
not have |
||||||||||||||||||||||
|
研究疾病: |
心脏瓣膜疾病 |
||||||||||||||||||||||
|
Target disease: |
heart valve disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
综上所述,本研究拟将衰弱整合模型运用于心脏瓣膜置换手术病人中,从生理,心理,社会三方面进行衰弱管理,检索有效的衰弱管理方法,基于衰弱整合模型构建科学的心脏瓣膜置换术病人术前衰弱管理方案,并探讨该方案对心脏瓣膜置换手术病人衰弱状态及预后的临床应用效果。为优化心脏瓣膜置换手术病人术前功能状态,改善病人预后,促进病人快速康复提供科学依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To sum up, this study intends to integrate the model of weakness applied to heart valve replacement surgery patients, from the physiological, psychological, social aspects of weakness management, to retrieve effective management methods of weakness, weakness based on integrated model to build a scientific heart valve replacement surgery patients before the weak management program, and to explore the program of heart valve replacement surgery patients with weak state and prognosis of clinical application. To provide scientific basis for optimizing the preoperative functional state of patients undergoing heart valve replacement surgery, improving the prognosis of patients and promoting the rapid rehabilitation of patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
本研究将比较两种不同的干预方法对心脏瓣膜置换术病人术前功能状态及预后的影响。以成年择期心脏瓣膜置换手术病人为研究对象,预期参加人数为76人,受试者可能被分配到干预组或对照组,对照组提供常规护理,干预组进行术前衰弱管理。干预组将根据病人的身体情况制定术前衰弱管理方案,在入院当天到术前一天为病人提供营养管理,指导病人进行功能锻炼,给予病人心理辅导,加强病人的社会支持。并于病人入院时,术前一天,术后一周,术后一个月,术后三个月通过门诊或电话的方式,采用问卷调查评估病人的衰弱情况、日常活动能力、焦虑抑郁情况、社会支持情况、生活质量、握力、5米步行速度。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
This study will compare the effects of two different interventions on preoperative functional status and prognosis in patients undergoing cardiac valve replacement. Adult patients undergoing elective heart valve replacement surgery were studied. The expected number of participants was 76. Participants could be assigned to either the intervention group, which provided routine care, or the control group, which provided preoperative frailty management. The intervention group will formulate a preoperative debilitating management plan according to the patient's physical condition, provide nutritional management for the patient from the day of admission to the day before surgery, guide the patient to carry out functional exercise, give psychological counseling to the patient, and strengthen the patient's social support. At admission, one day before operation, one week after operation, one month after operation and three months after operation, the patients were evaluated by questionnaire on weakness, daily activity ability, anxiety and depression, social support, quality of life, grip strength and 5-meter walking speed. |
||||||||||||||||||||||
|
纳入标准: |
1.计划行择期开胸心脏瓣膜置换手术的患者; 2.Tilburg衰弱评估量表评分≥ 5 分; 3.射血分数≥40% 4.纽约心脏病学会(NYHA)心功能分级为Ⅰ级-Ⅲ级; 5.预计手术等待时间至少为 1 周的心脏瓣膜置换术病人; 6.知情同意参与本研究的患者。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Patients scheduled for elective thoracotomy heart valve replacement surgery; 2. Tilburg frailty assessment scale score >=5; 3. Ejection fraction >=40%; 4. NYHA class I-III; 5. XVI Patients scheduled for heart valve replacement surgery with an expected waiting time of at least 1 week; 6. Patients who gave informed consent to participate in this study. |
||||||||||||||||||||||
|
排除标准: |
1.参与者需要紧急手术; 2.手术因病情变化而延迟; 3.临床症状不稳定以及任何导致显著症状或异常生命体征的患者; 4.合并严重的肝、脑、肾等脏器或其他严重躯体疾病; 5.精神异常、意识障碍、智力障碍等不能合作者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Participants need emergency surgery; 2. Delayed surgery due to changes in the condition; 3. Nnstable clinical symptoms and any patients who cause significant symptoms or abnormal vital signs; 4. Complicated with severe liver, brain, kidney and other organs or other serious body diseases; 5. Persons who are unable to cooperate with mental disorders, consciousness disorders, intellectual disabilities, etc. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-12-15 00:00:00至 To 2025-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-12-20 00:00:00 至 To 2025-07-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
公开时间: 研究成果经同行评议并正式发表后 6个月内(若因专利申请需延迟共享,最长不超过 12个月)。 共享方式: 通过公共数据平台 Figshare(https://figshare.com) 或领域专用数据库,数据经去标识化处理后上传。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Publication time: within 6 months after the research results are peer-reviewed and officially published (if the sharing is delayed due to patent application, the maximum time shall not exceed 12 months). Sharing method: upload data after de-identification through public data platform Figshare (https://figshare.com) or domain-specific database. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集:①量表资料由指定的资料收集者收集,收集资料时采用统一的指导语,患者填写完资料后当场检查填写的有效性,向患者核实无误后当场收回。②问卷数据采用 Excel 进行双人核对录入,确认数据无误后进行统计分析。③其他相关数据从病例记录表和医院电子采集和管理系统收集。 数据管理:①数据加密存储于阿里云平台,分角色权限访问,每日备份且保留10年。②研究结束后锁定数据库,经去标识化处理后通过Figshare平台(https://figshare.com)开放共享,全程遵循《个人信息保护法》及GDPR要求。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection: ① The scale data were collected by the designated data collector, and the unified instruction language was used when collecting the data. After the patients filled in the data, the validity of the filling was checked on the spot, and the data were retrieved on the spot after verification. ② Questionnaire data were checked and entered by Excel, and statistical analysis was carried out after confirming that the data were correct. ③Other relevant data were collected from case records and hospital electronic collection and management systems. Data management: ① Data is encrypted and stored on Alibaba Cloud platform, accessed by role permission, backed up daily and kept for 10 years. ② After the study, lock the database, de-identify it, and open it to share through Figshare platform (https://figshare.com), in full compliance with the Personal Information Protection Law and GDPR requirements. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |